In vivo drug action of tandospirone at 5-HT1A receptor examined using positron emission tomography and neuroendocrine response

Psychopharmacology

Volumn 165, Issue 1, 2002, Pages 37-42

  Nakayama, Takashi ^a,b,c   Suhara, Tetsuya ^b,c   Okubo, Yoshiro ^a,b,c   Ichimiya, Tetsuya ^b,c   Yasuno, Fumihiko ^b,c   Maeda, Jun ^b,c,d   Takano, Akihiro ^b,c   Saijo, Tomoyuki ^b,c   Suzuki, Kazutoshi ^b  

^a TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

^b NATIONAL INSTITUTE OF RADIOLOGICAL SCIENCES   (Japan)

^c JAPAN SCIENCE AND TECHNOLOGY AGENCY   (Japan)

^d 141 0032   (Japan)

Author keywords

5 HT1A receptor; 11C WAY 100635; Agonist; Growth hormone; PET; Tandospirone

Indexed keywords

GROWTH HORMONE; HYDROCORTISONE; N [2 [4 (2 METHOXYPHENYL) 1 PIPERAZINYL]ETHYL] N (2 PYRIDYL)CYCLOHEXANECARBOXAMIDE; SEROTONIN 1A RECEPTOR; TANDOSPIRONE;

ADULT; ARTICLE; BINDING AFFINITY; BODY TEMPERATURE; BRAIN REGION; CINGULATE GYRUS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DORSAL RAPHE NUCLEUS; DOUBLE BLIND PROCEDURE; DRUG MECHANISM; DRUG RESPONSE; GROWTH HORMONE BLOOD LEVEL; HIPPOCAMPUS; HUMAN; HYDROCORTISONE BLOOD LEVEL; IN VIVO STUDY; MALE; NEUROENDOCRINOLOGY; NORMAL HUMAN; PARIETAL LOBE; POSITRON EMISSION TOMOGRAPHY; PREFRONTAL CORTEX; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECEPTOR BINDING; TEMPORAL CORTEX;

ADULT; ANALYSIS OF VARIANCE; BODY TEMPERATURE; BRAIN; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; GROWTH HORMONE; HUMANS; HYDROCORTISONE; NEUROSECRETORY SYSTEMS; PIPERAZINES; PYRIDINES; PYRIMIDINES; RECEPTORS, SEROTONIN; RECEPTORS, SEROTONIN, 5-HT1; SEROTONIN AGONISTS; SEROTONIN ANTAGONISTS; TIME FACTORS; TOMOGRAPHY, EMISSION-COMPUTED;

EID: 0036932645     PISSN: 00333158     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00213-002-1234-8     Document Type: Article

References (41)

1. Anderson IM, Cowen PJ (1992) Effect of pindolol on endocrine and temperature responses to buspirone in healthy volunteers. Psychopharmacology 106:428-432
2. 1A receptors in the human brain confirmed with positron emission tomography. Psychopharmacology 144:303-305
3. 1A receptors and intrinsic activity. Eur J Pharmacol 386:97-103
4. Blier P, Seletti B, Young S, Benkelfat C, de Montigny C (1994) Serotonin 1A receptor activation and hypothermia: Evidence for a postsynaptic mechanism in humans. Neuropsychopharmacology 10:92S
5. 2-receptor blockade. J Neural Transm 76:91-98
6. Farde L, Ito H, Swahn CG, Pike VW, Halldin C (1998) Quantitative analyses of carbonyl-carbon-11-WAY-100635 binding to central 5-hydroxytryptamine-1A receptors in man. J Nucl Med 39:1965-1971
7. 1A receptor antagonist, WAY-100635. Eur J Pharmacol 281:81-88
8. Furchgott RF (1978) Pharmacological characterization of receptors: Its relation to radioligand-binding studies. Fed Proc 37:115-120
9. 1A receptors in rat brain membranes. Eur J Pharmacol 288:173-186
10. Goldenstein A, Aronow L, Kalman SM (1974) Principles of Drug Action, the Basis of Pharmacology, 2nd Edn. Wiley, New York
11. Grunder G, Wetzel H, Schlosser R, Anghelescu I, Hillert A, Lange K, Hiemke C, Benkert O (1999) Neuroendocrine response to antipsychotics: Effect of drug type and gender. Biol Psychiatry 45:89-97
12. 11C]WAY-100635 for PET. Neuroimage 8:426-440
13. Hamik A, Oksenberg D, Fischette C, Peroutka SJ (1990) Analysis of tandospirone (SM-3997) interactions with neurotransmitter receptor binding sites. Biol Psychiatry 28:99-109
14. Kenakin TP (1985) The quantification of relative efficacy of agonists. J Pharmacol Methods 13:281-308
15. 3H]WAY-100635, a novel 5-hydroxytryptamine1A receptor antagonist, to rat brain. J Neurochem 64:2716-2726
16. 3 Antagonists and Benzodiazepines: Their Comparative Behavioural Pharmacology. Wiley, Chichester, pp 343-363
17. Lammertsma AA, Hume SP (1996) Simplified reference tissue model for PET receptor studies. Neuroimage 4:153-158
18. 1B receptors. Eur J Pharmacol 244:77-87
19. 1A receptor responsivity in anxiety disorders and depression. Prog Neuropsychopharmacol Biol Psychiatry 15:723-733
20. 1A receptor activation in humans. Eur J Clin Pharmacol 39:17-19
21. 1A) receptor activation: Effects of 5-HT receptor and beta-adrenoceptor antagonists. J Clin Endocrinol Metab 70:670-674
22. 11C-carboxylation of an immobilized Grignard reagent. J Labelled Cpd Radiopharm 38:941-953
23. 11C]WAY 100635 and positron emission tomography in humans. Neuropsychopharmacology 24:209-229
24. 1A receptor-mediated regulation of plasma neuroendocrine hormones. J Pharmacol Exp Ther 271:1246-1252
25. Meller E, Goldstein M, Bohmaker K (1990) Receptor reserve for 5-hydroxytryptamine 1A-mediated inhibition of serotonin synthesis: Possible relationship to anxiolytic properties of 5-hydroxytryptamine1A agonists. Mol Pharmacol 37:231-237
26. Millan MJ, Rivet JM, Canton H, Le Marouille-Girardon S, Gobert A (1993) Induction of hypothermia as a model of 5-hydroxytryptamine1A receptor-mediated activity in the rat: A pharmacological characterization of the actions of novel agonists and antagonists. J Pharmacol Exp Ther 264:1364-1376
27. 11C]WAY100635 in humans: Comparison of arterial and reference tissue input functions. J Cereb Blood Flow Metab 20:1111-1133
28. 18F]MPPF. Psychopharmacology 155:193-197
29. 11C]WAY-100635. Eur J Pharmacol 301:R5-R7
30. Rabiner EA, Gunn RN, Castro ME, Sargent PA, Cowen PJ, Koepp MJ, Meyer JH, Bench CJ, Harrison PJ, Pazos A, Sharp T, Grasby PM (2000) Beta-blocker binding to human 5-HT(1A) receptors in vivo and in vitro: Implications for antidepressant therapy. Neuropsychophamacology 23:285-295
31. Schipper J, Tulp MTM, Berkelmans B, Mos J, van der Heijden JAM, Olivier B (1991) Preclinical pharmacology of flesinoxan: A potential anxiolytic and antidepressant drug. Hum Psychopharmacol 6:S53-S61
32. Schmidt ME, Risinger RC, Hauger RL, Schouten JL, Henry M, Potter WZ (1997) Response to alpha 2-adrenoceptor blockade by idazoxan in healthy male and female volunteers. Psychoneuroendocrionology 22:177-188
33. Seletti B, Benkelfat C, Blier P, Annable L, Gilbert F, de Montigny C (1995) Serotonin1A receptor activation by flesinoxan in humans. Body temperature and neuroendocrine responses. Neuropsychopharmacology 13:93-104
34. Shimizu H, Hirose A, Tatsuno T, Nakamura M, Katsube J (1987) Pharmacological properties of SM-3997: A new anxioselective anxiolytic candidate. Jpn J Pharmacol 45:493-500
35. Shimizu H, Karai N, Hirose A, Tatsuno T, Tanaka H, Kumasaka Y, Nakamura M (1988a) Interaction of SM-3997 with serotonin receptors in rat brain. Jpn J Pharmacol 46:311-314
36. Shimizu H, Tatsuno T, Hirose A, Tanaka H, Kumasaka Y, Nakamura M (1988b) Characterization of the putative anxiolytic SM-3997 recognition sites in rat brain. Life Sci 42:2419-2427
37. Shimizu H, Tatsuno T, Tanaka H, Hirose A, Araki Y, Nakamura M (1992) Serotonergic mechanisms in anxiolytic effect of tandospirone in the Vogel conflict test. Jpn J Pharmacol 59:105-112
38. Studholme C, Hill DL, Hawkes DJ (1997) Automated three-dimensional registration of magnetic resonance and positron emission tomography brain images by multiresolution optimization of voxel similarity measures. Med Phys 24:25-35
39. Taylor DP, Moon SL (1991) Buspirone and related compounds as alternative anxiolytics. Neuropeptides 19[Suppl]:15-19
40. Tsutsui S, Saitoh T, Katsura T (1992) Double blind comparative study of tandospirone (SM-3997) on neurosis - Placebo controlled dose-finding study (in Japanese). The Clinical Report 26:4265-4288
41. Yasuno F, Hasnine AH, Suhara T, Ichimiya T, Sudo Y, Inoue M, Takano A, Ou T, Ando T, Toyama H (2002) Template-based method for multiple volumes of interests of human brain PET images. Neuroimage (in press)